Search Result

Results for "

topoisomerase-IV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Topoisomerase (21) Antibiotic (24) Apoptosis (4) Bacterial (31) Beta-lactamase (1) DNA/RNA Synthesis (9) Isotope-Labeled Compounds (2) MicroRNA (3) Mitochondrial Metabolism (4) Orthopoxvirus (3) Reactive Oxygen Species (4)
By Research Areas:	Cancer (9) Infection (31) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Topoisomerase Glucokinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103399

Trovafloxacin mesylate 1 Publications Verification	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and *topoisomerase IV* activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-122139

Desethylene Ciprofloxacin hydrochloride	Bacterial	Infection
Desethylene Ciprofloxacin hydrochloride is a major metabolite of Ciprofloxacin (HY-B0356). Ciprofloxacin is an orally active topoisomerase IV inhibitor. Desethylene Ciprofloxacin hydrochloride has antibacterial activity .

HY-115990

Topoisomerase IV inhibitor 1	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 7d) is a potent *DNA topoisomerase IV* (TOPO IV) inhibitor with IC₅₀*s of 0.23 μM and 0.43 μM for TOPO* IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-115991

Topoisomerase IV inhibitor 2	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 5d) is a potent *DNA topoisomerase IV* (TOPO IV) inhibitor with IC₅₀*s of 0.35 μM and 0.55 μM for TOPO* IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-132923

NBTIs-IN-4	Bacterial	Infection
NBTIs-IN-4 demonstrates potent antibacterial activity against diverse Gram-positive pathogens, inhibition of both DNA gyrase and topoisomerase IV, a low frequency of resistance.

HY-N7066

Difloxacin hydrochloride	Bacterial Antibiotic	Infection
Difloxacin hydrochloride is a broad-spectrum antibacterial agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase and exhibits a concentration-dependant bactericidal effect by interference with the activity of DNA gyrase and topoisomerase IV .

HY-B0398

Nalidixic acid 1 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and *topoisomerase IV* and reversibly blocks DNA replication in susceptible bacteria .

HY-B0398A

Nalidixic acid sodium salt 1 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and *topoisomerase IV* and reversibly blocks DNA replication in susceptible bacteria .

HY-B0330A

Levofloxacin hydrate 5 Publications Verification Levofloxacin hemihydrate	Bacterial Antibiotic Topoisomerase DNA/RNA Synthesis Orthopoxvirus	Infection Cancer
Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and *topoisomerase IV*. Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrate shows anti-orthopoxvirus activity .

HY-B0330

Levofloxacin 5 Publications Verification (-)-Ofloxacin	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Orthopoxvirus	Infection Cancer
Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and *topoisomerase IV*. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity .

HY-109785A

(R)-Gyramide A hydrochloride	Bacterial	Infection
(R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that disrupts supercoiling activity with an IC₅₀ value of 3.3 µM. (R)-Gyramide A hydrochloride demonstrates antibacterial activity against E. coli, P. aeruginosa, and S. enterica (MICs of 10-80 µM). (R)-Gyramide A hydrochloride does not affect the closely related enzyme topoisomerase IV.

HY-B0330B

Levofloxacin hydrochloride 5 Publications Verification (-)-Ofloxacin hydrochloride
Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and *topoisomerase IV*. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrochloride shows anti-orthopoxvirus activity .

HY-B0330C

Levofloxacin sodium (-)-Ofloxacin sodium	Antibiotic Orthopoxvirus Bacterial DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and *topoisomerase IV*. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity .

HY-149925

DNA Gyrase-IN-6	Bacterial DNA/RNA Synthesis Topoisomerase	Infection
Antibacterial agent 138 is a benzothiazole inhibitor of bacterial DNA gyrase and *topoisomerase IV*. Antibacterial agent 138 exhibits favorable solubility and plasma protein binding. Antibacterial agent 138 has antibacterial activity against Gram-positive and Gram-negative strains. Antibacterial agent 138 is a dual GyrB and ParE inhibitor .

HY-B0356

Ciprofloxacin Maximum Cited Publications 23 Publications Verification Bay-09867	Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species	Infection Cancer
Ciprofloxacin (Bay-09867) is a potent, orally active *topoisomerase IV* inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .

HY-B0536

Clinafloxacin AM-1091; CI-960; PD 127391	Bacterial Antibiotic	Infection
Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin is against DNA gyrase and *topoisomerase IV* of S. aureus with IC₅₀ values of 0.92 µg/ml and 1.62 µg/ml, respectively .

HY-B0356B

Ciprofloxacin hydrochloride monohydrate Maximum Cited Publications 23 Publications Verification Bay-09867 hydrochloride monohydrate	Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species	Infection Cancer
Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active *topoisomerase IV* inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .

HY-B0536A

Clinafloxacin hydrochloride AM 1091 hydrochloride; CI 960 hydrochloride; PD127391 hydrochloride	Bacterial Antibiotic	Infection
Clinafloxacin hydrochloride (AM 1091 hydrochloride) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacterias, and anaerobic pathogens in vitro . Clinafloxacin hydrochloride is against DNA gyrase and *topoisomerase IV* of S. aureus with IC₅₀ values of 0.92 µg/ml and 1.62 µg/ml, respectively .

HY-B0398S

Nalidixic Acid-d5	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic Acid-d₅ is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1].

HY-B0356A

Ciprofloxacin monohydrochloride Maximum Cited Publications 23 Publications Verification Bay-09867 monohydrochloride	Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species	Infection Cancer
Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active *topoisomerase IV* inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .

HY-W040298

Ciprofloxacin lactate Bay-09867 lactate	Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species	Infection Cancer
Ciprofloxacin (Bay-09867) lactate is a potent, orally active *topoisomerase IV* inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .

HY-150044

*Type II topoisomerase* inhibitor 1**	DNA/RNA Synthesis Topoisomerase Bacterial	Infection
Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC₅₀: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits *topoisomerase IV* activity (IC₅₀: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area .

HY-10581A

Gatifloxacin hydrochloride 3 Publications Verification AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-10581B

Gatifloxacin mesylate AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

HY-10581

Gatifloxacin 3 Publications Verification AM-1155; BMS-206584; PD135432	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.

HY-10581C

Gatifloxacin sesquihydrate AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.

HY-B1050

Gemifloxacin mesylate SB-265805S; LB-20304a	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection
Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and *Topoisomerase IV* activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections .

HY-10581AS

Gatifloxacin-d3 hydrochloride AM-1155-d₃ hydrochloride; BMS-206584-d₃ hydrochloride; PD135432-d₃ hydrochloride	Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-A0170

Trovafloxacin 1 Publications Verification
Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and *topoisomerase IV* activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-B0268

Enoxacin AT 2266; CI 919	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268A

Enoxacin hydrate 1 Publications Verification Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268S1

Enoxacin-d8 hydrochloride	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

HY-16745

Lascufloxacin KRP-AM1977X	Beta-lactamase Bacterial Antibiotic	Infection
Lascufloxacin (KRP-AM1977X) is a potent and orally active fluoroquinolone antibacterial agent. Lascufloxacin potently inhibits infections caused by various pathogens, including quinolone-resistant strains. Lascufloxacin has the potential for various infectious diseases treatment, including lower respiratory tract infections .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0398

Nalidixic acid 1 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Resistance Selection Source classification Antibacterial Disease Research Disease Research Fields Other Antibiotics	Bacterial Antibiotic Topoisomerase
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and *topoisomerase IV* and reversibly blocks DNA replication in susceptible bacteria .

Cat. No.	Product Name	Chemical Structure

HY-B0268S1

Enoxacin-d8 hydrochloride
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

Enoxacin-d8 hydrochloride

Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

HY-B0398S

Nalidixic Acid-d5
Nalidixic Acid-d₅ is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1].

Nalidixic Acid-d5

Nalidixic Acid-d₅ is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1].

HY-10581AS

Gatifloxacin-d3 hydrochloride
Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

Gatifloxacin-d3 hydrochloride

Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks